- |||||||||| AN2718 / Pfizer, GSK, meropenem / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant K. pneumoniae. (Pubmed Central) - Sep 2, 2024
These promising data indicate that AN2718 has a high potential for being approved for the treatment of drug resistant bacterial infections, including those caused by the Ceftazidime-Avibactam resistant strains. To conclude, the compound AN2718 can be regarded as a valuable addition to the current antimicrobial armamentarium and a promising tool to combat antimicrobial resistance.
|
